ARTA
TTNP

A.R.T. Advisors’s Titan Pharmaceuticals TTNP Stock Holding History

A.R.T. Advisors’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-116
Closed -$89K – 1741
2019
Q2 		$89K Buy
116
+72
+164% +$65.8K 0.01% 1209
2019
Q1 		$47K Buy
+44
New +$42.7K ﹤0.01% 1217
2017
Q1 		– Sell
-4
Closed -$58K – 1723
2016
Q4 		$58K Buy
+4
New +$67.3K ﹤0.01% 1202

Other funds holding TTNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WPA
Winning Points Advisors Boca Raton, Florida $75.9M AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

A.R.T. Advisors's TTNP Position: Q3 2019 in Review

A.R.T. Advisors sold out of Titan Pharmaceuticals (TTNP) in Q3 2019, closing a stake of 116 shares — an estimated $89K sold.

A.R.T. Advisors first reported a position in TTNP in Q4 2016 and held it in 3 quarters. The position peaked at $89K in Q2 2019. 17 funds tracked by Wall St. Rank hold TTNP as of Q3 2019.

  • A.R.T. Advisors reported no remaining Titan Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 116 Titan Pharmaceuticals shares in Q3 2019, an estimated $89K.
  • A.R.T. Advisors first reported a position in Titan Pharmaceuticals in Q4 2016 and held it in 3 quarters.
  • A.R.T. Advisors's Titan Pharmaceuticals position peaked at $89K in Q2 2019.
  • 17 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q3 2019.

Based on A.R.T. Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.